UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 37.

Stahel, R A; Weder, W; Felley-Bosco, E; Petrausch, U; Curioni-Fontecedro, A; Schmitt-Opitz, I; Peters, S (2015). Searching for targets for the systemic therapy of mesothelioma. Annals of Oncology, 26(8):1649-1660.

Rechsteiner, M; Wild, P; Kiessling, M K; Bohnert, A; Zhong, Q; Stahel, R A; Moch, H; Curioni-Fontecedro, A (2015). A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib. Annals of Oncology, 26(1):246-248.

Echeverry, N; Ziltener, G; Barbone, D; Weder, W; Stahel, R A; Broaddus, V C; Felley-Bosco, E (2015). Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors. Cell Death and Disease, 6:e1757.

Joerger, M; Baty, F; Früh, M; Droege, C; Stahel, R A; Betticher, D C; von Moos, R; Ochsenbein, A; Pless, M; Gautschi, O; Rothschild, S; Brauchli, P; Klingbiel, D; Zappa, F; Brutsche, M (2014). Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer, 85(2):306-313.

Popescu, R A; Schäfer, R; Califano, R; Eckert, R; Coleman, R; Douillard, J-Y; Cervantes, A; Casali, P G; Sessa, C; Van Cutsem, E; de Vries, E; Pavlidis, N; Fumasoli, K; Wörmann, B; Samonigg, H; Cascinu, S; Cruz Hernández, J J; Howard, A J; Ciardiello, F; Stahel, R A; Piccart, M (2014). The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Annals of Oncology, 25(1):9-15.

Otterstrom, C; Soltermann, A; Opitz, I; Felley-Bosco, E; Weder, W; Stahel, R A; Triponez, F; Robert, J H; Serre-Beinier, V (2014). CD74: a new prognostic factor for patients with malignant pleural mesothelioma. British Journal of Cancer, 110(8):2040-2046.

Peters, Solange; Stahel, R A (2014). Successes and limitations of targeted cancer therapy. Basel: Karger.

Curioni-Fontecedro, A; Husmann, L; Soldini, D; Stahel, R A (2013). Primary non-small cell lung cancer response upon treatment with denosumab. Lung Cancer, 82(3):506-508.

Schaefer, N G; Veit-Haibach, P; Soyka, J D; Steinert, H C; Stahel, R A (2012). Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): Value of 18F-FDG-PET/CT. European Journal of Radiology, 81(1):e19-e25.

Shi, Y; Felley-Bosco, E; Marti, T M; Stahel, R A (2012). Differential effects of lovastatin on cisplatin responses in normal human mesothelial cells versus cancer cells: implication for therapy. PLoS ONE, 7(9):e45354.

Ziegler, A; Cerciello, F; Bigosch, C; Bausch-Fluck, D; Felley-Bosco, E; Ossola, R; Soltermann, A; Stahel, R A; Wollscheid, B (2012). Proteomic surfaceome analysis of mesothelioma. Lung Cancer, 75(2):189-196.

Felley-Bosco, E; Opitz, I; Soltermann, A; Thies, S; Weder, W; Stahel, R A (2011). Asbestos-induced tissue regeneration and malignant pleural mesothelioma: Insights from developmental studies. In: Berhardt, L V. Advances in Medicine and Biology. Volume 34. Hauppauge NY, USA: Nova Science Publishers, 131-153.

Arbogast, S; Behnke, S; Opitz, I; Stahel, R A; Seifert, B; Weder, W; Moch, H; Soltermann, A (2011). Automated ERCC1 Immunohistochemistry in Non-small Cell Lung Cancer: Comparison of anti-ERCC1 Antibodies 8F1, D-10, and FL-297. Applied Immunohistochemistry & Molecular Morphology, 19(2):99-105.

Shi, Y; Hollenstein, A; Felley-Bosco, E; Fraefel, C; Ackermann, M; Soltermann, A; Weder, W; Stahel, R A; Pruschy, M; Opitz, I (2011). Bioluminescence imaging for in vivo monitoring of local recurrence mesothelioma model. Lung Cancer, 71(3):370-371.

Sidi, R; Pasello, G; Opitz, I; Soltermann, A; Tutic, M; Rehrauer, H; Weder, W; Stahel, R A; Felley-Bosco, E (2011). Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis. European Journal of Cancer, 47(2):326-332.

Knobel, P A; Kotov, I N; Felley-Bosco, E; Stahel, R A; Marti, T M (2011). Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells. Neoplasia, 13(10):961-970.

Samaras, P; Blickenstorfer, M; Siciliano, R D; Haile, S R; Buset, E M; Petrausch, U; Mischo, A; Honegger, H; Schanz, U; Stüssi, G; Stahel, R A; Knuth, A; Stenner-Liewen, F; Renner, C (2011). Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. Annals of Hematology, 90(1):89-94.

Weder, W; Stahel, R A; Baas, P; Dafni, U; de Perrot, M; McCaughan, B C; Nakano, T; Pass, H I; Robinson, B W S; Rusch, V W; Sugarbaker, D J; van Zandwijk, N (2011). The MARS feasibility trial: conclusions not supported by data. Lancet Oncology, 12(12):1093-1094; author reply 1094.

Frauenfelder, T; Tutic, M; Weder, W; Götti, R P; Stahel, R A; Seifert, Burkhardt; Opitz, I (2011). Volumetry - an alternative to assess therapy response for malignant pleural mesothelioma? European Respiratory Journal, 38(1):162-168.

Stahel, R A; Weder, W; Lievens, Y; Felip, E (2010). Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 21(Suppl ):v126-v128.

Veit-Haibach, P; Schaefer, N G; Steinert, H C; Soyka, J D; Seifert, B; Stahel, R A (2010). Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer, 67(3):311-317.

Reck, M; Stahel, R A; von Pawel, J; Karthaus, M; Korfee, S; Serke, M; Schuette, W H W; Eschbach, C; Fink, T H; Leschinger, M I; Manegold, C (2010). Pemetrexed in the treatment of malignant mesothelioma: Results from an expanded access program in Germany. Respiratory Medicine, 104(1):142-148.

Soltermann, A; Opitz, I; Tischler, V; Thies, S; Morra, L; Stahel, R A; Weder, W; Moch, H (2010). EMT in NSCLC and malignant pleural mesothelioma. memo - Magazine of European Medical Oncology, 3(4):180-184.

Samaras, P; Buset, E M; Siciliano, R D; Haile, S R; Petrausch, U; Mischo, A; Honegger, H; Pestalozzi, B C; Schanz, U; Stüssi, G; Stahel, R A; Knuth, A; Renner, C; Stenner-Liewen, F (2010). Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation. Oncology, 79(1-2):93-97.

Stupp, R; Mayer, M; Kann, R; Weder, W; Zouhair, A; Betticher, D C; Roth, A D; Stahel, R A; Majno, S; Peters, S; Jost, L; Furrer, M; Thierstein, S; Schmid, R A; Hsu-Schmitz, S F; Mirimanoff, R O; Ris, H B; Pless, M (2009). Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncology, 10(8):785-793.

Thurneysen, C; Opitz, I; Kurtz, S; Weder, W; Stahel, R A; Felley-Bosco, E (2009). Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer, 64(2):140-147.

Stahel, R A; Weder, W (2009). Improving the outcome in malignant pleural mesothelioma: nonaggressive or aggressive approach? Current Opinion in Oncology, 21(2):124-130.

Stahel, R A; Felley-Bosco, E; Opitz, I; Weder, W (2009). Malignant pleural mesothelioma. Future Oncology, 5(3):391-402.

Stahel, R A; Weder, W; Felip, E (2009). Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 20 Sup:73-75.

Ribi, K; Bernhard, J; Schuller, J C; Weder, W; Bodis, S; Jörger, M; Betticher, D; Schmid, R A; Stupp, R; Ris, H B; Stahel, R A (2008). Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung Cancer, 61(3):398-404.

Stahel, R A (2008). Educational book of the 33rd ESMO Congress Stockholm, Sweden 12-16 September 2008. Introduction. Annals of Oncology, 19 Sup:vii22.

Gruber, G; Cole, B F; Castiglione-Gertsch, M; Stahel, R A (2008). Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Annals of Oncology, 19(8):1393-1401.

Santoro, A; O'Brien, M E; Stahel, R A; Nackaerts, K; Baas, P; Karthaus, M; Eberhardt, W; Paz-Ares, L; Sundstrom, S; Liu, Y; Ripoche, V; Blatter, J; Visseren-Grul, C M; Manegold, C (2008). Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. Journal of Thoracic Oncology, 3(7):756-763.

Viale, G; Regan, M M; Maiorano, E; Stahel, R A (2008). Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. Journal of Clinical Oncology, 26(9):1404-1410.

Stahel, R A; Weder, W; Felip, E (2008). Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 19(Suppl ):ii43-ii44.

Regan, M M; Pagani, O; Walley, B; et al; Stahel, R A (2008). Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Annals of Oncology, 19(7):1231-1241.

Viale, G; Giobbie-Hurder, A; Regan, M M; Stahel, R A (2008). Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. Journal of Clinical Oncology, 26(34):5569-5575.

This list was generated on Tue Jul 25 04:18:44 2017 CEST.